Vol. 141 No. 2122 (2011)
Sequential or concomitant chemotherapy in limited stage small-cell lung cancer
- K Khanfir
- M Elhfidh
- S Anchisi
- S Bieri
PURPOSE: Chemotherapy (CT) combined with radiation therapy (RT) is the standard treatment for limited disease small-cell lung cancer (LDSCLC). Many questions including RT dose, fractionation, and sequence of RT/CT administration remain controversial. In this paper, we retrospectively assessed the outcome of patients with LDSCLC treated with radiation of at least 50 Gy.
METHODS AND MATERIALS: From December 1997 to January 2006, 69 consecutive patients with LDSCLC were treated at our institutions. Treatment consisted of at least 4 cycles of CT, and 3D conformal thoracic RT. The median age was 61 years (range, 37–78 years). Sequential or concomitant CT/RT was given in 47 (68%) and 22 (32%) of the patients, respectively. The median RT dose was 60 Gy. Prophylactic cranial irradiation (PCI) was administered in 47 (68%) patients.
RESULTS: With a median follow-up of 36 months (range, 6–107), 16 patients were alive without disease. The median overall survival time was 24 months, with a 3-year survival rate of 29%. The 3-year disease-free survival (DFS) and loco-regional control (LRC) rates were 23% and 60%, respectively. A better DFS was significantly associated with performance status (PS) 0 (p = 0.004), complete response to treatment (p= 0.03), and PCI group (p = 0.03). A trend towards improved overall survival (OS) was observed for patients who underwent PCI (p = 0.07). Patients treated with sequential CT/RT had a better outcome than those treated with concomitant treatment (3-year DFS rate 27% vs. 13%; p = 0.04). However, PCI was delivered more frequently for the sequential group. No significant dose-response relationship was found in terms of LRC. The multivariate analysis showed that complete response to treatment was the only significant factor for OS.
CONCLUSION: Complete response to treatment was the most important factor for OS. A better DFS was significantly associated with the PCI group. We did not find a significant difference in outcome between patients receiving doses of 60 Gy or more and patients receiving 60 Gy or less.
- Perry MC, Eaton WL, Propert KJ, et al. Chemotherapy alone or chemotherapy with chest radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med. 1987;316:912–8.
- Pignon JP, Arriagada R, Ihde DC, et al. Meta-analysis of thoracic radiotherapy for small-cell lung cancer: unanswered questions. Squamous cell carcinoma of the anal margin. N Engl J Med. 1992;327:1618–24.
- Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol. 1992;10:890–5.
- Auperin A, Arriagada R, Pignon JP, Le Péchoux C, Gregor A, Stephens R, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med. 1999;341:476–84.
- Turrisi AT, Kyungmann K, Blum R,Sause WT, Livingstone RB, Komaki R, et al. Twice-daily compared with once daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340:265–71.
- Evans WK, Shepherd FA, Feld, et al. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol. 1985;3:1471–7.
- American Joint Committee on Cancer: AJCC cancer staging manual. New York: Springer; 2002.
- International Union Against Cancer: TNM classification of malignant tumours. New York: Wiley-Liss, Inc.; 1998.p.17–47.
- Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.
- Peto P, Pike MC, Armitage P, et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient: Part II. Br J Cancer. 1977;35:1–39.
- Beck-Bornholdt HP, Dubben HH. Potential pitfalls in the use of p-values and in interpretation of significance levels. Radiother Oncol. 1994;33:171–6.
- Trotti A, Colevas AD, Setser A, et al. CTCAE v.3: Development of a comprehensive Grading System for the adverse events of cancer treatment. Semin Radiat Oncol. 2003;13:176–81.
- Fried DB, Morris DE, Poole C, et al. Systematic review evaluating the timing of thoracic radiotherapy in combined-modality therapy for limited-stage small-cell lung cancer. J Clin Oncol. 2004;23:4785–93.
- Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited stage small-cell lung cancer. J Clin Oncol. 1993;11:336–44.
- De Ruysscher D, Pijls-Johannesma M, Van-steenkiste J, et al. Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited stage small-cell lung cancer. Ann Oncol. 2006:17;543–52.
- Jeremic B, Shibamato Y, Acimovic L, et al. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: A randomized study. J Clin Oncol. 1997;15:893–900.
- Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small – cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol. 2002;20:3054–60.
- Gregor A, Drings P, Burghouts J, et al. Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: A European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Study. J Clin Oncol. 1997;15:2840–9.
- Spiro SG, James LE, Rudd RM, et al. Early compared with late radiotherapy in combined-modality treatment for limited-disease small-cell lung: A London Lung Cancer Group multicenter randomized clinical trial and meta-analysis. J Clin Oncol. 2006;24:3823–30.
- Perry MC, Herndon JE III, Eaton WL, et al. Thoracic radiation therapy added to chemotherapy for small cell lung cancer: An update of Cancer and Leukemia Group B study 8083. J Clin Oncol. 1998,16:2466–7.
- Skarlos DV, Samantas E, Briassoulis E, et al. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrent with chemotherapy in limited-disease small-cell lung cancer: A randomized phase II study of the Hellenic Cooperative oncology group(HeCOG). Annal Oncol. 2001;12:1231–8.
- Albain KS, Crowly JJ, LeBlanc M, et al. Determinants of improved outcome in small-cell lung cancer: An analysis of the 2,850-patient Southwest Oncology Group data base. J Clin Oncol. 1990;8:1563–74.
- Sundstrom S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 year’s follow-up. J Clin Oncol. 2002;20:4665–72.
- Wolf M, Havemann K, Holle R, et al. Cisplatin/etoposide combination versus ifosfamide-etoposide combination in small-cell lung cancer: A multicenter German randomized trial. J Clin Oncol. 1987;5:1880–9.
- a Loehrer PJ Sr, Ansari R, Gonin R, et al. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: A Hoosier oncology group study. J Clin Oncol. 1995;13:2594–9.
- Thatcher N. Ifosfamide, carboplatin, etoposide (ICE) regimen in small cell lung cancer. Lung Cancer. 1993;9:51–4.
- Fetscher S, Brugger W, Engelhardt R, et al. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited-and extensive-disease small-cell lung cancer. Ann Oncol. 1997;8:49–56.
- Leyvraz S, Pampallona S, Martinelli G, et al. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: A randomized trial. JNCI. 2008;100:533–41.
- Glisson BS, Kurie JM, Perez-Soler R, et al. Cisplatin, etoposide and paclitaxel in the treatment of patients with extensive small cell lung carcinoma. J Clin Oncol. 1999;17:2309–13.
- Mavroudis D, Papadakis E, Georgoulias V, et al. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann Oncol. 2001;12:463–70.
- Baas P, Belderbos JSA, Senan S, et al. Concurrent chemotherapy (carboplatin, placlitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: a Dutch multicenter phase II study. BJC. 2006;94:625–30.
- Choi NC, Carey RW. Importance of radiation dose in achieving improved loco-regional tumor control in limited stage small-cell lung carcinoma. Int J Radiat Oncol Biol Phys. 1989;17:307–10.
- Roof KS, Fidias P, Lynch TJ, et al. Radiation dose escalation in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2003;57:701–8.
- Coy P, Hodson I, Payne DG, et al. The effect of dose of thoracic irradiation on recurrence in patients with limited stage small cell lung cancer. Initial results of a Canadian multicenter randomized trial. Int J Radiat Oncol Biol Phys. 1988;14:219–26.
- Bonner JA, Sloan JA, Shanahan TG, et al. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol. 1999;17:2681–91.
- Choi N, Herndon J, Rosenman J, et al. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol. 1998;16:3528–36.
- Bogart JA, Herndon JE, Lyss A, et al. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: Analysis of Cancer and Leukaemia Group B study 39808. Int J Radiat Oncol Biol Phys. 2004;59:460–8.
- Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small cell lung cancer. N Engl J Med. 2007;357:664–70.